Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 39 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1
• Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer RadiotherapyStatus unknownNCT04867564
• Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung CancerStatus unknownNCT04865705Phase 2
• Accelerating Lung Cancer Diagnosis Through Liquid BiopsyActive, not recruitingNCT04863924
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
• Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung CancerCompletedNCT04858204
• A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedNCT04856176Phase 2
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLCStatus unknownNCT04846452Phase 2
• A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLCStatus unknownNCT04840290Phase 3
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung CancerCompletedNCT04838548Phase 2
• Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
• Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung CancerActive, not recruitingNCT04836728Phase 2
• Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural DiseaseTerminatedNCT04836429Phase 1
• Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung CancerSuspendedNCT04835025
• A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826
• Expanded Access to Telisotuzumab VedotinTemporarily not availableNCT04830202
• Preoperative Lymph Node Staging With EBUS-TBNA in Clinical N0 Non Small-cell Lung CancerStatus unknownNCT04828850Not applicable
• Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
• Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard TreatmentsStatus unknownNCT04825925Not applicable
• A Study to Assess Safety of Nivolumab in Routine Oncology Practice in ChinaCompletedNCT04825873
• Keynatinib in Treated Patients with NSCLC and Brain MetastasesCompletedNCT04824079Phase 2
• Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.Active, not recruitingNCT04823377Not applicable
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Phase 3
• The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04818983
• A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04818333Phase 1/2
• To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionStatus unknownNCT04814056Phase 4
• Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2
• Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung CancerCompletedNCT04808050
• PF-07284892 in Participants With Advanced Solid TumorsTerminatedNCT04800822Phase 1
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownNCT04797806Phase 3
• Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.TerminatedNCT04797702Phase 1/2
• A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04794010
• Efficacy and Safety of Camrelizumab in Real-World Prospective StudyStatus unknownNCT04793139
• Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingNCT04791839Phase 2
• Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With PembrolizumabTerminatedNCT04791215
• Long-Term Follow-Up Study of Patients Receiving ATL001TerminatedNCT04785365Phase 2
• Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer PatientsCompletedNCT04776083Phase 3
• BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective EvaluationCompletedNCT04775095
• A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
• Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L OsimertinibCompletedNCT04769388Phase 2
• Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLCStatus unknownNCT04768491
• Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Phase 3
• Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCTerminatedNCT04765709Phase 2
• SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2
• First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesStatus unknownNCT04763083Phase 1
• BESPOKE Study of ctDNA Guided ImmunotherapyCompletedNCT04761783
• FL-101 in Surgically Resectable Non-Small Cell Lung CancerWithdrawnNCT04758949Phase 2
• Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung CancerStatus unknownNCT04758481Not applicable
• Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLCWithdrawnNCT04754815Phase 2
• Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung CancerActive, not recruitingNCT04751747Not applicable
• HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Phase 2/3
• Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung CancerStatus unknownNCT04749407
• Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and AnorexiaCompletedNCT04748523Not applicable
• Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabTerminatedNCT04748419Phase 1/2
• Genomic Study in Non-small Cell Lung Cancer Brain MetastasisCompletedNCT04745715
• Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2
• Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung CancerCompletedNCT04742192
• Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
• Cios Mobile 3D Spin for Robotic BronchoscopyCompletedNCT04740047
• CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedNCT04739358Phase 1/2
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedNCT04736173Phase 2
• A Phase 1/2 Study of SC-43 in Combination With CisplatinStatus unknownNCT04733521Phase 1/2
• Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung CancerCompletedNCT04732520Not applicable
• Toward High Fidelity Adaptive Radiotherapy in the ThoraxCompletedNCT04731571
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/2
• Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.Status unknownNCT04722406
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1
• Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation TherapyActive, not recruitingNCT04716946Phase 2
• Real-world Data of Nivolumab in Pre-treated NSCLCCompletedNCT04713462
• Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) ChemoradiotherapyActive, not recruitingNCT04711330
• Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLCCompletedNCT04710459Not applicable
• Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line TreatmentStatus unknownNCT04706949Phase 2
• Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung CancerTerminatedNCT04705025Not applicable
• LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04703153
• Functional Lung Imaging With DECT and 4DCTCompletedNCT04702607
• Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung CancerCompletedNCT04702009Phase 2/3
• A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLCWithdrawnNCT04699968Phase 2
• Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLCActive, not recruitingNCT04699721Phase 2
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingNCT04699188Phase 1/2
• NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) TrialTerminatedNCT04698681
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic DiseasesCompletedNCT04698161
• External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT04697446
• M1231 in Participants With Solid TumorsCompletedNCT04695847Phase 1
• Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette UseCompletedNCT04694846Not applicable
• Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).Status unknownNCT04690686Phase 2
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerActive, not recruitingNCT04685070Phase 2
• Gut Microbiota and Cancer Immunotherapy ResponseStatus unknownNCT04682327
• CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCCompletedNCT04681131Phase 2
• Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With PembrolizumabWithdrawnNCT04677361Early Phase 1
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1
• Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based ChemotherapyTerminatedNCT04676386
• Key Performance Indicators for the Assessment of NSCLC Patients PathwayCompletedNCT04676321
• Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer PatientsCompletedNCT04676009Not applicable
• Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownNCT04675008Phase 2
• A Real-world Study of Durvalumab for Lung Cancer in ChinaStatus unknownNCT04672759
• Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyStatus unknownNCT04670913Phase 2
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line TherapyCompletedNCT04670107Phase 1/2

← Carcinoma, Non-Small-Cell Lung overview